Navigation Links
Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019
Date:9/22/2010

BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to generic erosion of key agents, the colorectal cancer drug market will remain relatively flat over the next decade, increasing from more than $6.4 billion in 2009 to just under $6.7 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Colorectal Cancer reveal that the market leader -- Genentech/Roche/Chugai's Avastin -- will be minimally challenged in the colorectal cancer drug market over the next decade. Despite the emergence of biosimilar versions of Avastin, which is expected to begin in 2018, and increasing first-line use of other targeted agents, Avastin sales will decline only slightly from just over $2 billion in 2009 to $1.86 billion in 2019. Additionally, the entry of two new vascular endothelial growth factor (VEGF)-targeted agents into the market, Regeneron/Sanofi-Aventis's aflibercept (VEGF Trap) and ImClone Systems/Eli Lilly's ramucirumab, will fail to make a significant impact, together garnering only 4.9% of major market sales.

The Pharmacor 2010 findings also reveal that Bristol-Myers Squibb/ImClone Systems/Merck Serono's Erbitux dominates the epidermal growth factor receptor (EGFR) inhibitors class, mainly because it was first drug in its class to launch for the indication, it can be used in combination with chemotherapy and has been approved in Europe and Japan for use in the lucrative first-line setting.

"Through 2019, Erbitux's market share will grow incrementally, even in the face of biogeneric erosion and the use of additional anti-EGFR treatments in the first- and second-line settings," said Decision Resources Analyst Regina Jammen. "Erbitux's first-to-market position has helped establish it as the market-leading anti-EGFR therapy." '/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
2. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
3. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
4. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
5. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
6. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
7. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Medical Systems, Inc. (NASDAQ: CASM ) (CASMED), a ... that Thomas M. Patton , President and ... Annual Marcum MicroCap Conference on Thursday, May 30, 2013, at ... . The presentation is scheduled to begin ... will be available via a live webcast at http://wsw.com/webcast/marcum/casm/ ...
(Date:5/23/2013)... , May 23, 2013 Halozyme Therapeutics, ... the appointment of David A. Ramsay ... was most recently Vice President, Corporate Development at ... "With his established financial management experience ... by working in our commercial group for the ...
(Date:5/23/2013)... EarlySense, the market leader in ... for ,Best Novel Idea, at the 8 th ... Conference, hosted this year in the UK by the ... research team studying the impact of the EarlySense contact-free ... Los Angeles . The prize was awarded for ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4
... Capital, Inc. announced the initial closing of a private ... A total of 500,000 Units, each Unit consisting of ... purchase warrants, were sold, generating gross proceeds of approximately ... working capital and research and development related to Arrogene,s ...
... Conn., Jan. 19, 2012  The Specialty Photonics Division ... provider of optical fiber, cable, and assemblies for ... will present "Optical fibers with polyimide coatings for ... Dr. Stolov will present on Sunday, January 22nd ...
Cached Medicine Technology:WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering 2OFS to Present Paper on Optical Fibers with Polyimide Coatings for Medical Applications 2
(Date:5/24/2013)... (PRWEB) May 24, 2013 Patients who ... more likely to suffer from gastroesophageal reflux disease or ... reported in a study published today. , The article, ... Proximal Exposure as Measured by Hypopharyngeal Multichannel Intraluminal Impedance” ... could be of great importance to individuals who live ...
(Date:5/24/2013)... May 24, 2013 For the second ... Braeda Fresh Express Café to treat Tabitha Meals on ... to their door. More than 400 meal recipients recently ... the restaurants, along with the rest of a well-balanced, ... proud to partner with the Tabitha Meals on Wheels ...
(Date:5/24/2013)... With today’s levels of weight gain and ... on the causes of weight gain and how to lose ... causes of weight gain and treatments that will help patients ... released by the Child Study Center at NYU Langone Medical ... of ADHD and the soring rates of obesity later in ...
(Date:5/24/2013)... Today marks the launch of Destination Halifax’s ... , The redesigned and enhanced Itinerary Builder will help ... their computer or mobile device that they can send, ... users to fill in their date of arrival and ... choice of vacation packages, accommodations, restaurants, and things to ...
(Date:5/24/2013)... May 24, 2013 http://www.resource4thepeople.com/defectivedrugs/Zithromax-lawsuits.html ... the latest update involving allegations that the use ... (azithromycin) can allegedly cause potentially fatal irregular ... on May 17, 2013* that Health Canada has ... warning that Zithromax can cause abnormal changes in ...
Breaking Medicine News(10 mins):Health News:West Penn Allegheny Health System Physicians Pinpoint Gastroesophageal Reflux Disease (GERD) as a Factor That May Cause Chronic Cough 2Health News:Runza® Delivers Sandwiches, Draws Smiles from Tabitha Meals on Wheels Clients 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Help Patients with Weight Gain Linked to Childhood ADHD Lose Weight Fast 2Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 2Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 3Health News:2013 Alleged Zithromax Arrhythmia and Sudden Death Cases Update: Canadian Health Officials Issue Warning 4
... has been approved by the U.S. Food and Drug Administration (FDA) ... regimen to treat moderate to severe postmenopausal dyspareunia (painful sexual intercourse) ... ... COLLEGEVILLE, Pa. (Business Wire EON) November 13, 2008 -- ...
... of nest eggs, homes or jobs, their young children ... Michele C. Thorne, Ph.D., assistant professor of clinical psychology ... director of the Consult Liaison Service at Riley Hospital ... newborn babies pick up on the emotional tones of ...
... 13 SuperGen, Inc.,(Nasdaq: SUPG ), a ... novel cancer therapies, today announced that James S.,Manuso, ... to,present at the Lazard Capital Markets Fifth Annual ... St. Regis in New York, New York., ...
... Nov. 13 Dowden Health Media,s,beginnings were reflected in ... number 1 of the Dowden Dispatch an employee newsletter,which ... According to Mark Dowden, one of the founders ... one morning in 1988, as he stood,in his parents, ...
... providers join forces to provide superior customer care, ... Multi Vendor,Service announced today that it will form ... respected leaders in the ultrasound transducer repair,industry., ... brings together two of the most reputable,high-quality service ...
... seem to know exactly what types of cells to ... will inexplicably spare a seemingly identical group of neighbors. ... the kinds and amounts of proteins they produce - ... For this reason, scientists have struggled to parse the ...
Cached Medicine News:Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 4Health News:Helping children and teens deal with stress in an uncertain time 2Health News:Dowden Health Media: 20 Years and Growing 2Health News:MEDRAD Multi Vendor Service Forms Alliance with Wetsco 2Health News:MEDRAD Multi Vendor Service Forms Alliance with Wetsco 3Health News:Breakthrough in cell-type analysis offers new ways to study development and disease 2Health News:Breakthrough in cell-type analysis offers new ways to study development and disease 3Health News:Breakthrough in cell-type analysis offers new ways to study development and disease 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: